My Global Zone

Precision BioSciences unveils PBGENE-HBV, an innovative treatment showing promise in initial ELIMINATE-B trial results against chronic Hepatitis B. PBGENE-HBV integrates ARCUS-encoding mRNA within lipid nanoparticles, with no serious side effects reported in initial dosages. Participants from Moldova, Hong Kong, and New Zealand witnessed significant reductions in Hepatitis B surface antigen. Researchers plan to explore higher … Read more

Perion Network’s stock dropped nearly 12% following disappointing fourth-quarter financial results. Revenue fell short of expectations at $129.6 million, marking a year-over-year decline of almost 45%. Adjusted earnings per share decreased by 68% from the previous year. Projections for 2023 revealed a lower revenue forecast of $400 million to $420 million, below analysts’ expectations of … Read more

Genworth Financial reported a Q4 2024 net loss of $1 million but emphasized significant achievements and future growth prospects. Celebrating 20 years since its IPO, Genworth remains committed to supporting families through aging and retirement complexities. The Multiyear Rate Action Plan (MYRAP) achieved 87% of its anticipated value, reinforcing a strong $31.2 billion LTC book. … Read more

Louisiana-Pacific Corp (LPX) outpaced expectations with a 3.5% rise in net sales, reaching $681 million, driven by a 9% increase in siding revenue. The company strategically navigated a slight decline in OSB sales by focusing on volume, demonstrating adaptability in changing market conditions. Projected siding net sales for 2025 are poised to grow significantly, with … Read more

Nikola Corporation has filed for Chapter 11 bankruptcy, impacting the electric vehicle sector. The bankruptcy filing occurs as Nikola plans to auction its assets, with limited cash flow sustaining operations until March. The company’s HYLA fueling operations rely on finding partners to survive beyond spring. Founded in 2014, Nikola rose quickly after a high-profile SPAC … Read more

Teva Pharmaceutical Industries is undergoing a transformation from focusing on generic medicines to branded drugs and biopharmaceuticals. This year saw Teva’s stock rise 27.46%, although it experienced a 24.72% drop recently, highlighting market volatility. Under new leadership, Teva aims to improve execution, expand margins, and advance clinical trials. Despite a reduced number of hedge fund … Read more

The market reacted mildly to Stryker Corporation’s recent earnings dip, which was due to $1.3 billion in uncommon expenses. These expenses are viewed as temporary, suggesting potential future financial recovery. Stryker’s earnings per share have grown by an impressive 49% annually over the past three years. Despite current financial concerns, underlying growth signals suggest resilience … Read more

Smurfit Westrock Plc’s recent earnings report signals caution despite stable net income figures. The company’s share count doubled, diluting shareholder value and contributing to a 74% drop in earnings per share (EPS) over three years. A US$395 million impact from unusual items has further affected financial performance, though these may not recur. Future profit recovery … Read more

Wix.com surpasses Wall Street expectations with a notable rise in earnings per share to $1.93, up from $1.22 last year. Strategic enhancements and AI-driven innovations in Wix’s Studio platform are key to its impressive financial performance and growth. The advanced AI visual sitemap in Studio sets industry benchmarks, with Wix projecting further expansion by 2025. … Read more